Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

DNA AND CELL BIOLOGY, published by Mary Ann Liebert, Inc, is a distinguished journal in the realms of cell biology, genetics, and molecular biology, holding a notable position in its Q3 and Q2 quartile rankings across multiple academic categories as of 2023. With an ISSN of 1044-5498 and an E-ISSN of 1557-7430, this journal has been a pivotal platform for the dissemination of cutting-edge research since its inception in 1990, extending its coverage through 2024. Situated in the United States, the journal offers high-quality peer-reviewed articles, exploring significant advancements in biological sciences while fostering interdisciplinary collaborations within the research community. Though it currently does not offer open access, subscribed institutions and individual readers benefit from its rich repository of knowledge. The journal's rigorous standards and impactful content make it an essential resource for researchers, professionals, and students alike, aiming to stay at the forefront of discoveries influencing DNA and cellular dynamics.

Cardiovascular Toxicology is a pivotal journal dedicated to advancing the understanding of the interplay between toxic substances and cardiovascular health. Published by HUMANA PRESS INC, this journal serves as a critical resource for researchers and professionals in the fields of cardiology, toxicology, and molecular biology. With an ISSN of 1530-7905 and an E-ISSN of 1559-0259, it has established itself as a key source of high-quality research since its inception in 2001, continuing to contribute valuable insights through 2024. The journal enjoys a robust reputation, evidenced by its Q2 ranking in both Cardiology and Cardiovascular Medicine and Toxicology, along with a Q3 ranking in Molecular Biology for 2023. With Scopus rankings placing it in the 80th percentile for Cardiology and 71st for Toxicology, Cardiovascular Toxicology attracts submissions that reflect cutting-edge research and innovative methodologies. Notably, the journal prioritizes stringent peer review and scholarly rigor, ensuring that published works significantly impact the understanding of cardiovascular responses to various toxic agents. Though not an open-access journal, its content remains highly sought after in a diverse scholarly community, making it indispensable for those dedicated to enhancing cardiovascular disease prevention, diagnosis, and treatment through toxicological insights.

Genes and Environment is a premier interdisciplinary journal published by BMC that explores the dynamic interplay between genetic factors and environmental influences shaping health and behavior. Since its inception, the journal has gained recognition for its commitment to providing open access (since 2015) to groundbreaking research, fostering an inclusive platform for scholars worldwide. With an ISSN of 1880-7046 and an E-ISSN of 1880-7062, Genes and Environment consistently ranks in Q2 in Environmental Science, Q3 in Genetics, and Q2 in Social Psychology according to the 2023 category quartiles, highlighting its significant contributions to these fields. The journal is headquartered in the United Kingdom and has a diverse portfolio of research spanning from 2006 to 2024. It is recognized in Scopus with commendable rankings across various disciplines. By fostering dialogue among researchers, professionals, and students, Genes and Environment serves as a vital resource for understanding complex biological interactions with environmental factors, ultimately aiming to advance knowledge and inform public policy.

RNA is a premier journal in the field of molecular biology, published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT. With an impressive impact factor reflected by its Q1 status in the Molecular Biology category, this journal has established itself as an essential resource for researchers and professionals dedicated to understanding the role of RNA in biological processes. Spanning over two decades of impactful research from 1995 to 2024, RNA covers a broad spectrum of topics, including RNA biology, gene regulation, and therapeutic innovations. Researchers can access its extensive array of original research articles, reviews, and commentary, making it a vital conduit for new discoveries and methodologies in the field. With its high ranking within Scopus at Rank #115/410 and a 72nd percentile ranking in the domain of Biochemistry, Genetics, and Molecular Biology, RNA continues to advance the understanding of RNA and its critical contributions to life sciences.

AGING CELL is a premier peer-reviewed journal published by Wiley, specializing in the rapidly evolving field of aging research and cell biology. Established in 2002 and enjoying an impressive track record as evidenced by its Q1 ranking in both Aging and Cell Biology categories for 2023, the journal has become a vital resource for researchers and professionals alike. With a significant impact factor highlighting its scholarly influence, AGING CELL offers an open access model since 2014, ensuring that groundbreaking research is accessible to the global community. The journal covers a wide array of topics related to the mechanisms of aging at the cellular and molecular levels, making it essential reading for anyone invested in understanding the complexities of aging processes and their implications for health and disease. With a broad international readership based in the United Kingdom and beyond, AGING CELL is dedicated to disseminating high-quality research that impacts scientific understanding and fosters advances in the field.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.